Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Times Interest Earned (2021 - 2025)

BioNexus Gene Lab's Times Interest Earned history spans 5 years, with the latest figure at -$108.38 for Q3 2025.

  • For Q3 2025, Times Interest Earned rose 49.82% year-over-year to -$108.38; the TTM value through Sep 2025 reached -$75.65, down 81.04%, while the annual FY2024 figure was -$74.42, 60.03% up from the prior year.
  • Times Interest Earned for Q3 2025 was -$108.38 at BioNexus Gene Lab, up from -$125.29 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $89.48 in Q2 2023 and bottomed at -$593.69 in Q3 2023.
  • The 5-year median for Times Interest Earned is -$28.18 (2024), against an average of -$78.81.
  • The largest YoY upside for Times Interest Earned was 250.41% in 2023 against a maximum downside of 1986.25% in 2023.
  • A 5-year view of Times Interest Earned shows it stood at -$11.39 in 2021, then soared by 167.13% to $7.64 in 2022, then soared by 122.49% to $17.01 in 2023, then tumbled by 265.69% to -$28.18 in 2024, then plummeted by 284.64% to -$108.38 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Times Interest Earned are -$108.38 (Q3 2025), -$125.29 (Q2 2025), and -$125.98 (Q1 2025).